The unmet need in AML continues to be quite high. despite the advances in cancer research. The key requirement is for a more effective treatment that reduces the high rate of relapsed/refractory disease in AML4. The emerging treatment options focus on biomarkers, such as FLT3, CD33, RARA+ and TP53, and show promise for specific sub-groups of patients. A similar trend is being observed for the relapsed/refractory segment as well, with multiple promising therapies in development; however, only time will tell whether these therapies can reduce the burden of the disease.